Enlivex Therapeutics Ltd.
ENLVDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
Sep 4, 2026
18dMarket Overview
Stock performance and key metrics
2 upcoming, 1 past
How ENLV's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Allocetra | Phase 2 | Osteoarthritis, Knee | - | - |
Allocetra-OTS | Phase 2 | Sepsis | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Enlivex Therapeutics Ltd.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Enlivex Therapeutics Ltd.'s (ENLV) pipeline across Phase 2. Its lead program is Allocetra (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Enlivex Therapeutics Ltd.'s next FDA catalyst?→
Enlivex Therapeutics Ltd.'s (ENLV) next tracked catalyst is a Earnings expected September 4, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ENLV biotech catalysts?→
Add ENLV to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Enlivex Therapeutics Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.